Lexicon’s Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials

Ads

You May Also Like

Profound Medical Announces Second Quarter 2018 Financial Results

TORONTO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or ...

Neovacs and Lupus Europe Join Voices on World Lupus Day

PARIS and BOSTON, May 10, 2017 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader ...

Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge

Transaction to result in NASDAQ-listed company focused on developing novel RNA medicines and technologiesArcturus ...